By using this site, you are consenting to our use of cookies. To find out more visit our privacy policy.
Includes articles, courses, and CPGs. Unlimited access for APTA members.
Mar 21, 2018/Review
Adding trigger point dry needling to an exercise program for patients with chronic shoulder pain may be more cost-effective than exercise alone, according to a recent clinical trial.
Mar 14, 2018/News
"The Good Stuff," is an occasional series that highlights recent media coverage of physical therapy and APTA members, with an emphasis on good news and stories of how individual PTs and PTAs are transforming health care and society every day.
Mar 7, 2018/Review
A JAMA has concludes that the drugs probably don't even do that much, at least not any more effectively than nonopioid medications.
Mar 6, 2018/Review
Nearly a third of patients prescribed physical activity have functional limitations that could interfere with their ability to follow the directives.
Mar 5, 2018/Review
Researchers have found that for individuals with chronic noncancer pain, opioids probably aren't delivering.
Feb 27, 2018/News
The "Choosing Wisely" continues to expand—this time, into pediatric orthopedics.
Feb 20, 2018/News
Health care spending is projected to rise by 5.3% in 2018 and continue at about that growth rate through 2026, according to estimates from CMS.
Feb 14, 2018/News
A major advocacy issue for the physical therapy profession was resolved with the elimination of the hard cap on therapy services under Medicare, but other provisions in the massive budget bill that ended the hard cap have created different challenges in the home health arena.
"The Good Stuff," is an occasional series that highlights recent, mostly local media coverage of physical therapy and APTA members, with an emphasis on good news and stories of how individual PTs and PTAs are transforming health care and society every day.
Feb 13, 2018/News
CMS has released details on how it will process claims made as a result of its decision to cover supervised exercise therapy (SET) in the treatment of peripheral artery disease (PAD).